Murakami Masashi | Department Of Biochemistry Cancer Institute Okayama University Medical School
スポンサーリンク
概要
- MIYAZAWA Masakiの詳細を見る
- 同名の論文著者
- Department Of Biochemistry Cancer Institute Okayama University Medical Schoolの論文著者
関連著者
-
Murakami Masaru
Department of Obstetrics and Gynecology, Tokai University School of Medicine
-
Osamura R.yoshiyuki
東海大学教育・研究支援センター
-
Yasuda M
Department Of Pathology Tokai University School Of Medicine
-
Yasuda Masanori
Department Of Pathology School Of Medicine Tokai University
-
Yasuda Masanori
Department of Pathology, Saitama Medical University International Medical Center
-
Makino Tsunehisa
Departments Of Obstetrics And Gynecology Tokai University
-
Makino Tsunehisa
東海大学 医学部産婦人科学
-
Muramatsu Toshinari
Department Of Obstetrics And Gynecology School Of Medicine Tokai University
-
Kajiwara Hiroshi
Department of Pathology, Tokai University School of Medicine
-
Osamura Robert
Dep. Of Pathology Tokai Univ. School Of Medicine
著作論文
- An Up-to-Date Anti-Cancer Treatment Strategy Focusing on HIF-1α Suppression : Its Application for Refractory Ovarian Cancer
- Mutated RAS Induced PLD1 Gene Expression through Increased Sp1 Trascription Factor
- Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germ-cell tumor-like differentiation
- Immunohistochemical Expression of Type-1 Carbohydrate Antigens : Availability of DU-PAN-2 on Pathological and Clinical Aspects
- Uterine body cancer mass screening at Tokai University Hospital
- Serum carbohydrate antigen elevations in endometrial adenocarcinomas : Characterization of DU-PAN-2 expression as a tumor marker
- Modification of p53 Immunoexpression Associated with Chemotherapy Regimens in Advanced and Refractory Ovarian Cancers(Prof. K Watanabe Memorial Article)
- IS-6 Induction of specific cytotoxic T-lymphocyte (CTL) responses in patients with cervical cancer using an human papillomavirus (HPV)-16 E7 peptide and autologous dendritic cells
- Clinicopathological Analysis of DU-PAN-2 as a Tumor Marker for Endometrial Adenocarcinoma in Comparison with CA19-9
- IS-22 Impact of Whole-Body FDG-PET for the Detection of Metastatic Tumors in Recurennt/Advanced Gynecological Malignancies